Sanofi Aktie
102,98
EUR
+0,20
EUR
+0,19
%
102,96
EUR
+0,28
EUR
+0,27
%
Diese Analysten bewerten die Sanofi-Aktie
Analyst | Kursziel | Abstand Kursziel | Datum | |
---|---|---|---|---|
Deutsche Bank AG | 85,00 EUR | -17,33% | 12.09.2024 | |
Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | 115,00 EUR | +11,85% | 10.09.2024 | |
Bernstein Research | 114,00 EUR | +10,87% | 03.09.2024 | |
JP Morgan Chase & Co. | 100,00 EUR | -2,74% | 02.09.2024 | |
Jefferies & Company Inc. | 120,00 EUR | +16,71% | 02.09.2024 | |
DZ BANK | - | - | 26.07.2024 | |
UBS AG | 110,00 EUR | +6,98% | 26.07.2024 | |
Barclays Capital | 105,00 EUR | +2,12% | 04.04.2024 |
Kursziele im Branchenvergleich
Aktie | Buy | Hold | Sell | Ø Kursziel | Abst. Kursziel |
---|---|---|---|---|---|
Abbott Laboratories | 0 | 0 | 0 | - | - |
Allergan Inc. | 0 | 0 | 0 | - | - |
Amgen Inc. | 0 | 0 | 0 | - | - |
AstraZeneca PLC | 5 | 3 | 1 | 137,64 GBP | - |
Bayer | 1 | 9 | 0 | 31,89 EUR | +18,20% |
BioNTech (ADRs) | 0 | 4 | 1 | 93,40 USD | -11,05% |
CanSino Biologics Inc. Registered Shs -A- | 0 | 0 | 0 | - | - |
CureVac | 0 | 1 | 0 | - | - |
EVOTEC SE | 3 | 1 | 1 | 11,60 EUR | +90,63% |
GSK PLC Registered Shs | 4 | 4 | 1 | 18,79 GBP | +15,27% |
Johnson & Johnson | 0 | 0 | 0 | - | - |
Merck Co. | 0 | 0 | 0 | - | - |
Merck KGaA | 6 | 1 | 0 | 185,67 EUR | +9,96% |
Moderna Inc | 2 | 1 | 0 | 166,33 USD | +138,71% |
MorphoSys | 1 | 3 | 0 | 35,38 EUR | - |
Mylan N.V. | 0 | 0 | 0 | - | - |
Novartis AG | 3 | 6 | 1 | 99,56 CHF | +1,55% |
Novavax Inc. | 0 | 0 | 0 | - | - |
Pfizer Inc. | 3 | 3 | 0 | 31,40 USD | +7,68% |
Roche Holding AG (Inhaberaktie) | 0 | 0 | 0 | - | - |
Sanofi S.A. | 5 | 2 | 1 | 107,00 EUR | +4,07% |
Shanghai Fosun Pharmaceutical (Group) Co Ltd (A) | 0 | 0 | 0 | - | - |
Sinopharm Group Co Ltd (H) | 0 | 0 | 0 | - | - |
Sinovac Biotech LtdShs | 0 | 0 | 0 | - | - |
STADA | 0 | 0 | 0 | - | - |
Teva Pharmaceutical Industries Ltd. (spons. ADRs) | 0 | 0 | 0 | - | - |
Valneva | 0 | 0 | 0 | - | - |
Warner Chilcott plc | 0 | 0 | 0 | - | - |